European committee backs Novo Nordisk ’ s once-weekly Type II diabetes therapy

A panel of experts from the European Medicines Agency issued a positive recommendation today for Novo Nordisk‘s (NYSE:NVO) once-weekly diabetes drug, Ozempic. The committee’s recommendation will need to be endorsed by the European Commission before the insulin-maker’s product can be formally marketed in the EU. Get the full story at our sister site, Drug Delivery Business News. The post European committee backs Novo Nordisk’s once-weekly Type II diabetes therapy appeared first on MassDevice.
Source: Mass Device - Category: Medical Devices Authors: Tags: Diabetes Pharmaceuticals Regulatory/Compliance Wall Street Beat Novo Nordisk Source Type: news